Device Trial Radar · NCT06925477
Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
51
Planned (sponsor's estimate)
Start
Aug 7, 2025
Primary completion
Oct 31, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares two laser treatments for open-angle glaucoma: Selective Laser Trabeculoplasty (SLT) and Direct Selective Laser Trabeculoplasty (DSLT). SLT is a widely used procedure that requires a manual technique with a goniolens, while DSLT is a new, automated, non-contact method using the Eagle system. The study will evaluate whether DSLT is as effective as SLT in reducing intraocular pressure (IOP). Participants will be randomly assigned to receive either treatment and will be monitored over 12 months to assess changes in IOP, medication use, and safety outcomes. The goal is to determine if the simpler DSLT procedure can provide similar results to SLT, potentially improving patient comfort and access to glaucoma care.
Conditions
- GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Interventions
DSLT treatment for Open-Angle GlaucomaDevice
This intervention aims to determine the efficacy and safety of Direct Selective Laser Trabeculoplasty (DSLT) in reducing intraocular pressure in patients with open-angle glaucoma.
SLT treatment for Open-Angle GlaucomaDevice
To determine the efficacy and safety of using Selective Laser Trabeculoplasty for treatment of open-angle glaucoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MUSC Health West Ophthalmology Clinic
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.